Why and how are peptide–lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes  by Matsuzaki, Katsumi
Review
Why and how are peptide^lipid interactions utilized for self-defense?
Magainins and tachyplesins as archetypes
Katsumi Matsuzaki *
Graduate School of Biostudies, Kyoto University, Yoshida-Shimoadachi-Cho 46-29, Sakyo-ku, Kyoto 606-8501, Japan
Accepted 5 October 1999
Abstract
Animals as well as plants defend themselves against invading pathogenic microorganisms utilizing cationic antimicrobial
peptides, which rapidly kill various microbes without exerting toxicity against the host. Physicochemical peptide^lipid
interactions provide attractive mechanisms for innate immunity. Many of these peptides form cationic amphipathic
secondary structures, typically K-helices and L-sheets, which can selectively interact with anionic bacterial membranes by the
aid of electrostatic interactions. Rapid, peptide-induced membrane permeabilization is an effective mechanism of
antimicrobial action. This review article summarizes interactions with lipid bilayers of magainins (K-helix) and tachyplesins
(L-sheet) discovered in frog skin and horseshoe crab hemolymph, respectively, as archetypes, emphasizing that the mode of
interaction is strongly dependent on the physicochemical properties not only of the peptide, but also of the target
membrane. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
During the last decade, a large number of antimi-
crobial peptides have been discovered from animals
as well as plants [1^4]. These molecules, which are
either constitutive or inducible, are recognized as im-
portant components of innate defense mechanisms
and are present on mucosal surfaces, on the body
surface, and within the granules of phagocytes. These
peptides are typically composed of 12^45 amino acid
residues. Table 1 summarizes several representative
peptides. The following four features are required
of the antimicrobial peptides as the ¢rst step of
self-defense against invading pathogenic microorgan-
isms (see Fig. 5). (1) Selective toxicity; the peptides
should discriminate between host and microbial cells.
(2) Fast killing; the time needed for bacterial killing
should be much shorter than the doubling time of
the target bacteria, which is 20 min in the case of
Escherichia coli. (3) Broad antimicrobial spectra; de-
sirably a single species of peptide is e¡ective against
many species of microorganisms. (4) No resistance
development; the peptide should have such a mech-
anism of action that the bacteria cannot easily devel-
op resistance against it.
For selective toxicity and broad spectra, the pep-
tides should target those molecules which are ubiq-
uitous in prokaryotic cells, but rarely or never
present in eukaryotic cells. Development of resist-
ance is considered to be di⁄cult if the target mole-
cules are important components conserved among
microorganisms. For rapid killing, the site of action
should preferably be the cell surface rather than the
cell interior.
To ful¢l these requirements, many of the self-de-
fense peptides act on cytoplasmic membranes of mi-
croorganisms, which are functional analogs of the
mitochondrial inner membranes of eukaryotic cells
with cytochromes and other enzymes of the respira-
tory chain. The host utilizes physicochemical pep-
tide^lipid interactions to permeabilize the mem-
branes, as will be described in the following
sections. However, it should be noted that some pep-
tides have been suggested to exhibit bactericidal ac-
tivity via mechanisms other than membrane perme-
abilization [5].
The membrane-acting peptides have common
physicochemical properties; they are highly basic
(cationic) due to the presence of multiple Lys and
Arg residues and form amphipathic secondary struc-
tures (K-helix and L-sheet), which can be accommo-
dated into membranes. In this paper, the interactions
of magainins and tachyplesins with lipid bilayers and
bacterial membranes will be reviewed as archetypes
of K-helical and L-sheet peptides, respectively. Only
key references and recent progress regarding magai-
nins will be summarized to avoid overlap of the re-
cent review on this topic [6]. It should be noted that
protegrins from polymorphonuclear neutrophils
show three-dimensional structures and membrane in-
teractions similar to those of tachyplesins, although
the primary structures are quite di¡erent from each
other [7^10].
2. Magainins and tachyplesins
Magainins were discovered from the granular
gland of the skin of the African clawed frog Xenopus
laevis by Zaslo¡ in 1987 [11]. In the narrow sense,
magainins denote two 23-residue peptides, magainins
1 and 2 (Table 1). However, the amidated forms of
magainins and other related peptides such as PGLa
of the same origin [12] have often been called ‘mag-
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ainins’. Magainins exhibit a broad spectrum of anti-
microbial activity against bacteria, fungi, and proto-
zoa typically in the concentration range of 10^100
Wg/ml [3,11,13^16]. In contrast, more than 1 mg/ml
is needed to lyse mammalian cells, e.g. erythrocytes
[17]. That is, the peptides are selectively toxic against
microorganisms.
The tachyplesin family peptides were isolated from
the hemocytes of horseshoe crabs. The yield was as
high as tens of milligrams per 100 g wet weight of the
tissue. Tachyplesin I was ¢rst found from Tachypleus
tridentatus in 1988 [18]. Tachyplesins II and III and
polyphemusins I and II from other species followed
thereafter [19,20]. These molecules are composed of
17^18 amino acid residues and have unique primary
structures that contain three tandem repeats of a
tetrapeptide, hydrophobic amino acid-Cys-aromatic
amino acid-Arg and an amidated C-terminus (Table
1). Methods of chemical synthesis have been estab-
lished [21,22]. These peptides are more active than
magainins with minimum inhibitory concentrations
for bacteria and fungi in the range of 1^10 Wg/ml
[3,16,18,19,23], whereas hemolysis becomes signi¢-
cant at 0.1 mg/ml [17,24].
3. Membrane lipids as target
These peptides are considered to kill bacteria by
permeabilizing and/or disrupting bacterial mem-
branes. Addition of magainin 2 [16] or tachyplesin
I [24,25] to E. coli (Gram-negative) or Staphylococcus
aureus (Gram-positive) cells induces the e¥ux of in-
tracellular K ions and concomitant reduction in cell
viability. The lethal event appears to be depolariza-
tion of the inner membranes, preceded by permeabi-
lization of the outer membranes in the case of Gram-
negative bacteria [16,26,27].
The fundamental architecture of biomembranes is
the lipid bilayer, in which membrane proteins are
Table 1
Representative antimicrobial peptides
aAcidic and basic residues are underlined and shown in bold face, respectively.
bTachyplesin I was also isolated from T. gigas and Carcinoscorpius rotundicauda.
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embedded in a mosaic fashion. Magainins, like other
membrane-acting antimicrobial peptides, appear to
target the lipid matrix rather than the proteins be-
cause enantiomeric peptides composed of D-amino
acids exhibit the same potency as naturally occurring
all-L peptides, indicating that chiral molecules are not
involved in the antimicrobial action [15,28]. Indeed,
magainins [29^33] and tachyplesins [25,34] induce
permeabilization of arti¢cial lipid bilayers (vesicles
and planar lipid bilayers).
4. Selective toxicity
The most striking di¡erence in cytoplasmic mem-
branes between prokaryotic and eukaryotic cells is
the composition and topological arrangement of lip-
ids [35]. The surface (outer lea£et) of mammalian cell
membranes is exclusively composed of electrically
neutral, zwitterionic phospholipids, mainly phospha-
tidylcholine (PC) and sphingomyelin, whereas bacte-
rial membranes contain large amounts of negatively
charged phospholipids, phosphatidylglycerol (PG)
and cardiolipin (CL), although their asymmetric dis-
tribution between the two lea£ets is not well known
(Fig. 1). The anionic lipids should be exposed to the
outer lea£et to a signi¢cant extent because the acidic
lipid contents sometimes exceed 50% [36]. The outer
membranes of Gram-negative bacteria are covered
with polyanionic lipopolysaccharides (LPS).
The activity of magainins and tachyplesins is
highly sensitive to the lipid composition of the target
membrane. The lipid speci¢city can explain the selec-
tive toxicity [17,37]. These peptides selectively bind to
and permeabilize anionic membranes [17,25,29^
31,38]. The driving forces of binding are hydropho-
bic interactions between the non-polar amino acids
and the hydrophobic core of the membrane, and
electrostatic interactions between the positive charges
of the peptides and the negative charges of the lipids.
The hydrophobicities of the self-defense peptides are
generally too low to e¡ectively associate with zwit-
terionic phospholipids, avoiding toxicity against the
host. In contrast, those of venoms and toxins are
relatively high [17]. For example, the binding con-
stant of bee venom melittin to PC bilayers is
4.5U104 M31 [39], which is much greater than that
of magainin 2 amide (55 M31) [40]. The large pos-
itive charges of the antimicrobial peptides enable se-
lective binding to bacterial membranes through elec-
trostatic interactions (Fig. 1). For example, the
presence of a surface potential as small as 320 mV
can enhance the apparent binding constant of tachy-
plesin I (7+) by approximately 200-fold at physiolog-
ical temperature. The observation that magainins
and tachyplesin I show higher antibacterial activity
against bacteria with membranes containing larger
amounts of acidic lipids also supports this hypothesis
[16].
Another major di¡erence in chemical composition
of membranes between prokaryotic and eukaryotic
cells is that the latter are abundant in sterols,
although some prokaryotes contain sterols or hepa-
noids, which are similar to sterols [41]. The presence
of membrane-stabilizing cholesterol has been shown
to protect human erythrocytes from attack by mag-
ainin 2 (Fig. 1) [17].
5. Molecular mechanisms of membrane
permeabilization
As will be shown later in detail, peptide^lipid in-
Fig. 1. Molecular basis for membrane discrimination by antimi-
crobial peptides. Cationic peptides preferentially bind to bacteri-
al membranes with abundant acidic phospholipids by the aid of
electrostatic interactions. The outer lea£ets of mammalian cell
membranes are exclusively composed of zwitterionic phospho-
lipids, for which the peptides show only low a⁄nity. The pres-
ence of cholesterol also contributes to the resistance of the
membranes against the peptides.
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teractions are time-dependent. Therefore the investi-
gator should always bear in mind which state is
being observed at any given time. The conformation
and orientation of magainins and tachyplesins de-
scribed here are considered to be those in an equi-
librium or ‘quasi-equilibrium’ state.
5.1. Conformation of peptides in lipid bilayers
In the hydrophobic environment of lipid bilayers
where no hydrogen-bonding groups exist, antimicro-
bial peptides form intramolecular or intermolecular
hydrogen bonds, folding into amphipathic secondary
structures. Magainins including PGLa have little or
no well-de¢ned secondary structure in aqueous solu-
tions at neutral pH, whereas the peptides essentially
assume K-helical structures (helicity 60^90%) upon
binding to acidic phospholipid bilayers as revealed
by circular dichroism [29,30,42^45], vibrational [46^
48], and NMR spectroscopy [48,49]. As shown in
Fig. 2, magainin 2 and PGLa can form ideal amphi-
pathic helices with polar angles of V180‡ and
V100‡, respectively.
NMR studies showed that in contrast to magai-
nins, tachyplesin I forms a cyclic antiparallel L-sheet
connected by a type II L-turn even in aqueous sol-
ution because of the two disul¢de bridges (Fig. 3)
[50,51]. The sheet is not perfectly amphipathic; the
Arg5^Arg14 pair are aligned opposite to the Arg15^
Arg17 pair. This unique structure may be important
for the peptide^LPS interaction [51]. The sheet struc-
ture is rigid except for the £exible N- and C-terminal
tails. The Trp2 residue is fully accessible to an aque-
ous quencher, acrylamide (Stern^Volmer constant
8.7 M31) [25]. The peptide also assumes an antipar-
allel L-sheet conformation in acidic phospholipid bi-
layers as revealed by Fourier transform infrared
(FTIR) spectroscopy [38]. The Trp residue in the
membrane is completely shielded from the quencher
and is located close to the interface [25]. Although
tachyplesin I adopts an antiparallel L-sheet structure
in both the aqueous and membrane phases, minor
alterations of the peptide backbone and side chain
orientations have been suggested to occur upon
membrane binding [52,53].
A linear tachyplesin I analog (T-Acm), in which
the four SH groups of tachyplesin I are protected by
acetamidomethyl groups, also forms an antiparallel
L-sheet in membranes [38]. The lower wavenumber
(1620 cm31) of the amide I vibration compared with
that of tachyplesin I (1630 cm31) suggests stronger
interchain hydrogen bonding. T-Acm shows several-
fold weaker antimicrobial activities compared with
cyclic tachyplesin I [23].
5.2. Orientation of peptides in lipid bilayers
The lipid bilayer is composed of a hydrophilic po-
lar head group region and a hydrophobic core,
although recent studies have emphasized a more
complicated nature of the interfacial region [54]. Am-
Fig. 3. The space ¢lling model of the solution structure of ta-
chyplesin I [51]. The molecule is shown orthogonal to the mean
plane of the L-sheet. The shaded atoms represent the side-chain
nitrogens.
Fig. 2. Helical wheel representation of magainin 2 and PGLa.
The shaded area indicates the hydrophobic surfaces of the am-
phipathic helices.
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phipathic secondary structures can be accommodated
in the membranes with the hydrophobic amino acid
side chains embedded in the hydrocarbon core and
the polar side chains interfacing with water. There-
fore, the antimicrobial peptides essentially lie parallel
to the membrane surface (Fig. 4). Solid-state NMR
[49,55] and £uorescence quenching experiments [56]
revealed that the helix lies parallel to the membrane
surface. Analysis by FTIR-polarized attenuated total
re£ection spectroscopy indicated that the sheet
planes of tachyplesin I and T-Acm are also on the
membrane surface [38].
It is also possible for the peptides to adopt a trans-
membrane orientation. In this case, to avoid unfav-
orable exposure of the polar residues to the lipid
hydrocarbon chains, the peptides should self-aggre-
gate, forming an aqueous pore in the center. The
magainin 1 helix starts to be inserted perpendicular
to the membrane surface above a peptide to lipid
ratio (P/L) of 1/30 [57]. The parallel-to-perpendicular
orientational transition is closely related to peptide-
induced membrane perturbation, as will be described
below.
5.3. Peptide-induced curvature stress in membranes
The incorporation of ‘aliens’ causes stress in the
lipid bilayer, leading to membrane perturbation.
When the unfavorable energy reaches a threshold,
the membrane barrier property becomes lost, which
is the basis of the antimicrobial action of these pep-
tides. Relatively less hydrophobic magainin 2 shows
shallow penetration into the hydrocarbon core. The
Trp residue of F5W-magainin 2 is located approxi-
mately 1 nm from the bilayer center [56]. This loca-
tion pushes the lipid polar head groups aside, forcing
a gap to form in the hydrophobic region. The mem-
brane locally becomes thinner to ¢ll the gap. An X-
ray study revealed that the bilayer thickness de-
creases almost linearly with increasing peptide con-
centration [58]. The expansion of the polar region
implies the local induction of positive curvature
strain. Indeed, magainins raise the lamellar-to-hexag-
onal II phase transition temperature of dipalmito-
leoylphosphatidylethanolamine (DPoPE), indicating
that the peptides inhibit formation of the inverted
structure of negative curvature by imposing positive
curvature strain [44,59].
The membrane thinning quadratically increases
membrane deformation energy, destabilizing the sur-
face-lying state [60]. When the energy reaches a crit-
ical value, the peptide starts to adopt a transmem-
brane orientation (A in Fig. 4). The critical P/L at
which the transition occurs depends strongly on lipid
composition and the extent of hydration as shown
for alamethicin [61].
Several transmembrane peptides constitute an
aqueous pore, through which ions can pass. In the
case of magainins, the pore structure is di¡erent from
the ‘barrel-stave’ pore constructed solely by a bundle
Fig. 4. Mechanisms of membrane permeabilization by antimicrobial peptides. (A) Peptides imposing positive curvature strain on mem-
branes by expanding the polar head group region form the ‘toroidal’ pore, unless strongly inhibited by the bilayer. The peptides can
translocate into the inner lea£et upon disintegration of the pore. (B) In the presence of negative curvature-inducing lipids, large
amounts of peptides (P/LW1/10) are accumulated on the bilayer surface, eventually leading to irreversible membrane disruption.
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of helices [62] in that lipids are intercalated between
helices (Fig. 4). This may be due to stronger inter-
actions between the positively charged side chains of
the peptides and the anionic phospholipid head
groups. The ‘dynamic, peptide^lipid supramolecular
complex pore’ model was originally proposed by the
author based on the observation that magainin 2
induces rapid lipid £ip-£op coupled with pore forma-
tion [63]. The £ip rate is identical to the £op rate and
is independent of lipid species. Such phenomena can
be explained by lateral di¡usion of membrane lipids
between the two monolayers which are connected by
the pore. A few months later, Huang and colleagues
succeeded in detecting the toroidal structure using
neutron scattering [64] and named it the ‘toroidal
(wormhole) pore’. Magainins thus exert their cyto-
toxicity by simultaneously dissipating the transmem-
brane potential and the lipid asymmetry against
membranes of certain lipid compositions. The pore
allows leakage of calcein (MW 623), but is imperme-
able to £uorescein isothiocyanate-dextran of MW
4400. The pore diameter has been estimated to be
2^3 nm [45,64].
Tachyplesin I also forms a calcein-permeable pore
in liposomes, but it is still unknown if lipids are also
involved in the pore structure [25,34].
The hypothesis that positive curvature strain im-
posed by the peptides triggers pore formation is sup-
ported by the observation that the incorporation of
negative curvature-inducing phosphatidylethanol-
amine (PE) inhibits pore formation of magainin 2
[44] and tachyplesin I [34]. As an extreme case, if
the membrane su¡ers from high intrinsic negative
curvature strain, magainin 2 breaks the bilayer or-
ganization instead of forming pores (B in Fig. 4).
The peptide e¡ectively forms pores in PG bilayers
at low P/L, well below 1/100 with the vesicle mor-
phology intact. In contrast, if phosphatidylserine,
phosphatidic acid, or CL is used as an acidic phos-
pholipid, membrane permeabilization occurs only at
much higher P/L (1/50 to 1/10) with some morpho-
logical changes in the liposomes [44]. A rapid de-
crease and a subsequent gradual increase in light
scattering were observed. These lipids form inverted
phases under conditions of reduced interlipid repul-
sion, such as low pH or high salt concentration [65^
67]. The binding of the cationic peptide locally neu-
tralizes the bilayer charge, imposing strong negative
curvature strain, which counteracts peptide-induced
pore formation. This allows accumulation of a large
amount of the peptide in the membrane, ¢nally lead-
ing to membrane disruption. The modulation of
membrane permeabilization mechanisms by the
physicochemical properties of lipid bilayers is quite
important for understanding of the antimicrobial
mechanisms of action. Membrane permeabilization
by pore formation can be, at least partially, compen-
sated by ion channels and pumps in bacterial mem-
branes because membrane organization is intact. In
contrast, peptide-induced membrane disruption is ir-
reversible and unrecoverable, inevitably leading to
cell death.
The toroidal pore has a positive curvature in the
direction of the membrane normal. However, the
pore-lining lipids would exhibit negative curvature
parallel to the membrane plane (Fig. 4, top view).
Therefore, peptides with narrower polar faces more
e¡ectively form pores. The pore formation rate of
PGLa (polar angle W100‡) is much larger than
that of magainin 2 (polar angle W180‡) [45]. A de-
crease in magainin polar angle enhances membrane
permeabilization activity [59]. The balance between
positive and negative curvature would depend on
the pore size, larger pores having predominantly pos-
itive curvature [68].
Shai et al. proposed the ‘carpet-like’ mechanism
for the mode of action of cecropins and dermaseptins
[69,70]. In this mechanism, a large amount of peptide
covers the membrane surface and disrupts bilayer
organization similarly to a detergent. The authors
consistently used PS as an acidic phospholipid, which
prefers the mechanism shown by B in Fig. 4. These
peptides may follow the scheme shown by A in Fig. 4
in PG membranes.
5.4. Translocation of peptides across lipid bilayers
The pore shown in Fig. 1 has a ¢nite lifetime. An
increase in the peptide’s positive charge reduces pore
stability because of enhanced electrostatic repulsion
between the side chains [43]. Magainin 2 and PGLa
stochastically translocate into the inner monolayer
upon disintegration of the pores. Translocation is
completely coupled to pore formation and lipid
£ip-£op [45,63,71]. The pore formation-translocation
mechanism was also observed for tachyplesin I,
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although it is not clear if the peptide triggers lipid
£ip-£op [34]. Interestingly, linear T-Acm does not
follow this scheme, disrupting bilayer organization
instead of forming a pore [34]. The incorporation
of PE facilitates membrane permeabilization, corrob-
orating the hypothesis that the mechanism of action
of T-Acm is di¡erent from that of cyclic tachyplesin
I.
The pore formation-translocation proceeds in sec-
onds to minutes depending on the P/L used. A re-
duction in the peptide density in the outer lea£et due
to translocation signi¢cantly reduces the rate of sub-
sequent pore formation because pore formation is a
cooperative process. Therefore, the system reaches a
quasi-equilibrium state where pores no longer exist.
Since it is in this state that peptide orientation and
aggregation have been investigated, it is not surpris-
ing that neither transmembrane orientation nor pep-
tide aggregation have been detected.
5.5. Peptide^peptide association
Magainin 2 forms a dimer with a small association
free energy of 8.8 kJ/mol [45]. It is possible that the
formation of a small fraction of aggregates inducing
signi¢cant membrane perturbation triggers mem-
brane permeabilization. This may be why high P/L
values around 1/300 are needed to permeabilize the
most susceptible PG bilayers. There have been no
studies on the self-association of tachyplesins.
Association between di¡erent peptides has also
been reported. Magainin 2 and PGLa of the same
origin (Xenopus skin) form a 1:1 stoichiometric com-
plex of high potency in membranes with an associa-
tion free energy of 15 kJ/mol [45], exhibiting marked
synergism [31,45,72,73].
5.6. Peptide^outer membrane interactions
The peptides are expected to bind to negatively
charged cell walls before reaching the ultimate target,
cell membranes. In the case of Gram-negative bacte-
ria, the major component of the cell wall is the outer
membrane, which acts as a strong permeability bar-
rier to various antibiotics [74]. The outer lea£et of
the outer membrane is mainly built up from poly-
anionic LPS, which consists of a polysaccharide moi-
ety and a covalently linked moiety called lipid A.
Despite its importance, there have been relatively
few studies concerning LPS^peptide interactions.
Magainin 2 induces blebs on the surface of E. coli
cells [16]. Blazyk and collaborators found using outer
membrane^peptidoglycan complexes that magainins
perturb the lipid organization of the membrane [75^
77]. Recently, a novel model system for outer mem-
branes, LPS/phospholipid liposomes, has been devel-
oped [78]. Magainin 2 forms a helix upon binding to
LPS, permeabilizing the membrane. The lipid A moi-
ety appears to be the binding site. Double di¡usion
experiments demonstrated that tachyplesins form
complexes with LPS [18,19].
6. Concluding remarks
Host defense based on peptide^lipid interactions is
a reasonable mechanism from various viewpoints
(Fig. 5). Cationic peptides target cell-surface anionic
lipids abundant and ubiquitous exclusively in micro-
organisms. This simple electrostatic discrimination
provides selective toxicity (line 5) as well as broad-
spectrum antimicrobial activities (line 6). Further-
Fig. 5. Why and how are peptide^lipid interactions utilized for
self-defense? The physicochemical mechanisms (line 2) on cell
surface (line 1) contribute to rapid killing of bacteria and to
prevention of resistance development because resistance mecha-
nisms such as enzymatic degradation or export processes will
not circumvent the antimicrobial action (line 3). Development
of resistance is di⁄cult because the target molecules (anionic
lipids) are important components conserved among microorgan-
isms (line 4). The simple electrostatic discrimination provides
selective toxicity (line 5) as well as broad-spectrum antimicro-
bial activities (line 6). To avoid toxicity, the membrane-permea-
bilizing mechanisms are so designed as to work only at higher
P/L values (line 7).
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more, the rather lenient molecular recognition makes
development of resistance di⁄cult (line 4). Highly
speci¢c interactions such as enzyme^substrate and
receptor^ligand could be obviated by mutation. The
amphipathic peptides can weakly bind to host cell
membranes through hydrophobic interactions. To
avoid toxicity, the membrane-permeabilizing mecha-
nisms are so designed as to work only at higher P/L
values (s 1/300), which may be related to the weak
tendency of peptide oligomerization (line 7). The
driving force of membrane permeabilization appears
to be mainly peptide-induced stress in bilayer organ-
ization. Therefore, the detailed molecular mecha-
nisms are strongly dependent on not only the pep-
tide, but also the lipid composition (Fig. 4). The
physicochemical mechanisms (line 2) on cell surface
(line 1) contribute to rapid killing of bacteria and to
prevention of resistance development (line 3) because
resistance mechanisms such as enzymatic degrada-
tion or export processes will not circumvent the anti-
microbial action.
Analysis of the antimicrobial peptides also re-
vealed a dynamic aspect of peptide^lipid interactions
that had not been recognized previously. Highly
charged peptides with MW of several thousands
can easily cross lipid bilayers by transiently forming
peptide^lipid supramolecular complex pores. The
scheme shown in Fig. 4 can also be viewed as the
peptide^lipid system constituting a physicochemical
signal transduction system; the translocation of an
amphipathic peptide quantitatively generates two
coupled signals, i.e. ion £ow and lipid £ow, which
short circuit the otherwise insulated two aqueous
phases and two lipid monolayers, respectively.
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